Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 9/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | HTR2B | P41595 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338470 | 1.00 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL338471 | 1.00 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL339102 | 0.98 | MTNR1B (0.38) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL339103 | 0.98 | MTNR1B (0.38) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL805876 | 0.84 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL14327017 | 0.81 | MTNR1A (0.42) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL1646076 | 0.81 | MTNR1B (0.39) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL12394472 | 0.80 | MTNR1A (0.40) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL803827 | 0.80 | MTNR1A (0.41) | MTNR1BMTNR1AHTR2CHTR2AHTR2B | |
| SCHEMBL339505 | 0.76 | MTNR1B (0.36) | MTNR1BMTNR1AHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207949-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Watson Pharma Private Limited (IN) | 2011-08-25 | — | — | US | disclosed |
| US-20110207949-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Watson Pharma Private Limited (IN) | 2011-08-25 | — | — | US | disclosed |
| EP-0885210-B2 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008062468-A2 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE INDENO [5,4-B] FURAN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062468-A2 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE INDENO [5,4-B] FURAN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| EP-1550655-A1 | Bicyclic intermediates | Takeda Pharmaceutical Company Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207949-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | CYP2B6, CYP2A6, UGT1A6 | MTNR1B 111/4885MTNR1A 190/4885HTR2C 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.